RNA-Seq in Drug Discovery and Development | Agenda Bookshop Skip to content
LAST CHANCE! Order items marked '10-20 working days' TODAY to get them in time for Christmas!
LAST CHANCE! Order items marked '10-20 working days' TODAY to get them in time for Christmas!
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Feng Cheng
B01=Robert Morris
Category1=Non-Fiction
Category=MBGR
Category=PNRP
Category=PS
Category=TDCW
COP=United Kingdom
Delivery_Pre-order
Language_English
PA=Not yet available
Price_€50 to €100
PS=Forthcoming
softlaunch

RNA-Seq in Drug Discovery and Development

English

The research and development process in modern drug discovery and development is a complex and challenging task. Using traditional biological test methods such as PCR to measure the expression levels or function of these genes is costly and time-consuming. RNA-seq can measure the expression patterns of thousands of genes simultaneously and provide insights into functional pathways or regulations in biological processes, which has revolutionized the way biological scientists examine gene functions. This book addresses the various aspects of the RNA-seq technique, especially its application in drug discovery and development.

Features

One of the few books that focuses on the applications of the RNA-seq technique in drug discovery and development.

Comprehensive and timely publication which relates RNA sequencing to drug targets, mechanisms of action, and resistance.

The editor has extensive experience in the field of computational medicinal chemistry, computational biophysics, and bioinformatics.

Chapter authors are at the frontline of the academic and industrial science in this particular area of RNA sequencing.

See more
Current price €53.19
Original price €55.99
Save 5%
Age Group_Uncategorizedautomatic-updateB01=Feng ChengB01=Robert MorrisCategory1=Non-FictionCategory=MBGRCategory=PNRPCategory=PSCategory=TDCWCOP=United KingdomDelivery_Pre-orderLanguage_EnglishPA=Not yet availablePrice_€50 to €100PS=Forthcomingsoftlaunch

Will deliver when available. Publication date 19 Dec 2024

Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 19 Dec 2024
  • Publisher: Taylor & Francis Ltd
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9781032004099

About

Feng ChengDr. Cheng is a computational biologist. He received systematic training in bioinformatics at Chinese Academy of Science University of Illinois at Urbana Champaign Rice University University of Virginia and Yale University. His researches mainly focus on applications of bioinformatics methods for the identifications of drug-drug interactions (DDIs) and for drug repositioning by analyzing Big Data from public resources. He is also interested in computer-aided drug design. Dr. Cheng has published over 50 research papers in prestigious journals including Nature Neuron J. Am. Chem. Soc and Scientific Reports. His work has been cited more than 1600 times. Presently Dr. Cheng is an editor board member of Journal of Proteomics and Bioinformatics and the Open Bioinformatics Journal. Dr. Cheng has been serving as a peer reviewer for more than ten journals.Robert MorrisMr. Morris is a computational biologist with an M.S in molecular biology and is currently working on his MPH in applied biostatistics. His research primarily is focused on using bioinformatic tools to identify drug-drug interactions as well as identify risk factors associated with elevated risk of adverse drug reactions including bradycardia and dysphagia using publicly available Big Data. He also is focused on elucidating drug mechanisms using bioinformatics and RNA sequencing techniques. He currently has 10 publications in a variety of journals including the Journal of Alzheimers Disease and Brain Science. Finally he has recently served as a peer reviewer for the Drugs Real World Outcomes (DRWO) journal.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept